ANGO ANGIODYNAMICS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1275187 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY-2.6%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR—
Margins
Gross margin55.7%
Operating margin-11.2%
Net margin-10.1%
FCF margin0.4%
EBITDA margin-4.3%
Returns
ROE-19.2%
ROA-13.0%
ROIC (approx.)-21.4%
Asset turnover1.28x
Leverage & solvency
Liabilities / assets32.2%
Debt / equity0.00x
Current ratio2.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.11x
Accruals ratio-14.4%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 |
|---|---|---|
| Income statement | ||
| Revenue | $320.17M | $292.50M |
| Cost of revenue | $145.28M | $134.79M |
| Gross profit | $174.89M | $157.71M |
| R&D expense | $29.45M | $26.22M |
| SG&A expense | $43.69M | $42.09M |
| Operating income | -$39.93M | -$39.95M |
| Pretax income | -$36.30M | -$34.03M |
| Income tax | $442,000 | -$39,000 |
| Net income | -$36.74M | -$33.99M |
| EBITDA | -$16.97M | -$14.15M |
| EPS (basic) | -0.88 | -0.83 |
| EPS (diluted) | -0.88 | -0.83 |
| Weighted avg. shares (diluted) | 41.53M | 40.85M |
| Balance sheet | ||
| Cash & equivalents | $53.86M | $55.89M |
| Receivables | $48.33M | $42.89M |
| Inventory | $52.44M | $62.01M |
| Current assets | $163.39M | $168.32M |
| PP&E, net | $27.10M | $32.30M |
| Intangibles | $67.21M | $69.12M |
| Total assets | $267.16M | $280.14M |
| Current liabilities | $74.72M | $76.20M |
| Total liabilities | $96.34M | $97.17M |
| Shareholders' equity | $170.82M | $182.97M |
| Shares outstanding | 41.70M | 40.99M |
| Cash flow statement | ||
| Operating cash flow | $3.09M | -$10.13M |
| Capital expenditure | $2.58M | $4.46M |
| Free cash flow | $508,000 | -$14.59M |
| Investing cash flow | -$5.95M | -$10.18M |
| Financing cash flow | $564,000 | -$255,000 |
| Depreciation & amortization | $22.95M | $25.80M |
| Stock-based compensation | $13.96M | $9.77M |
| Share buybacks | $0 | $1.67M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.